Immunic Inc (IMUX)
Immunic, Inc. is a NASDAQ-listed biotechnology company focused on the development of selective oral therapies for chronic inflammatory and autoimmune diseases. The company’s lead program, IMU-838, is in Phase 3 and Phase 2 clinical development for relapsing and progressive multiple sclerosis as well as moderate-to-severe ulcerative colitis. Immunic is also advancing IMU-856, which is entering Phase 2 testing for restoring intestinal barrier function in a range of gastrointestinal diseases, including celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other related conditions. In addition, IMU-381 remains in preclinical development for gastrointestinal disorders. Founded in 2016, Immunic is headquartered in New York, New York, and maintains operations in the United States and Germany.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMUX
|
$13.34
|
23.1% Upside
|
Undervalued
|
$43.09
|
297.5% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
1.2x
|
147.9 M
|
-6.625 M
|
0.4%
|
87.3%
|
-6.1
|
78.9%
|
